CONVERGENCE

of Laboratory Diagnostics and Population Health

6TH ANNUAL

CLINICAL LAB 2.0 WORKSHOP

March 6-7, 2023 • Pendry Chicago

View the 2023 Agenda

Project Santa Fe Foundation’s

2023 CL2.0 Workshop

CONVERGENCE

Join fellow leaders across the industry to explore the convergence of laboratory diagnostics and population health.

A HIGH-TOUCH, HIGHLY INTERACTIVE, LIMITED SEATING EVENT

We invite you to participate in two days of exclusive dialogue and invention, as we address critical questions that will shape the future of our collective industry.

The potential value of the clinical lab does not end at the time we release a result — rather that’s where it begins.

convergenve set up 3mod

Connect with thought leaders from around the globe

With an exclusive curriculum developed by the Project Santa Fe Foundation distinguished board of directors, our 2023 Workshop will include:

  • Hands-on roundtables
  • Cross-industry collaborations
  • Facilitated hot-topic panels and discussions
  • Engaging, informative dialogue with your peers
VIEW AGENDA

Join Us at the Hotel Pendry Chicago

Steeped in history, anchored in style, and set within the iconic 1929 Art Deco Carbide & Carbon building in Chicago’s loop neighborhood, Pendry Chicago is a modern luxury hotel that pays homage to both the past and the present.

You will find Pendry Chicago’s interiors contemporary and comfortable, designed with an eye for the Carbide & Carbon building’s illustrious Art Deco heritage and combined with a modern vision of luxury hospitality.

Screenshot 2023-01-30 at 5.23.47 PM

CL2.0 Workshop: CONVERGENCE led by Project Santa Fe Foundation Board of Directors

Khosrow R. Shotorbani, MBA, MT(ASCP)

BOARD OF DIRECTORS / PRESIDENT, EXECUTIVE DIRECTOR, PSFF; FOUNDER, CEO, LAB 2.0 STRATEGIC SERVICES

Khosrow Shotorbani is the CEO and founder of the Lab 2.0 Strategic Services, LLC. He is a member of Project Santa Fe Clinical Laboratory 2.0 industry advocate. As the former President and Chief Executive Officer at TriCore Reference Laboratories, Mr. Shotorbani oversaw the corporate direction and strategy of TriCore, focusing on leadership and innovation, as well as operations, growth, and the financial health of the company. He led TriCore’s initiatives based on the premise to improve health outcomes and lower costs by utilization of laboratory data.

Mr. Shotorbani was instrumental in the creation of Project Santa Fe—a recently launched initiative with like-minded executives—helping to forge new frontiers that will define future economic valuation and placement of diagnostic services. Before joining TriCore in 2014, Mr. Shotorbani served as Senior Vice President and Director of Business Development/Business Innovations at ARUP. He joined ARUP in 1984 as a medical technologist and while at ARUP advanced to positions with progressive responsibility over his 30-year tenure.

Khosrow R. Shotorbani, MBA, MT(ASCP)

BOARD OF DIRECTORS / PRESIDENT, EXECUTIVE DIRECTOR, PSFF; FOUNDER, CEO, LAB 2.0 STRATEGIC SERVICES

Khosrow Shotorbani is the CEO and founder of the Lab 2.0 Strategic Services, LLC. He is a member of Project Santa Fe Clinical Laboratory 2.0 industry advocate. As the former President and Chief Executive Officer at TriCore Reference Laboratories, Mr. Shotorbani oversaw the corporate direction and strategy of TriCore, focusing on leadership and innovation, as well as operations, growth, and the financial health of the company. He led TriCore’s initiatives based on the premise to improve health outcomes and lower costs by utilization of laboratory data.

Mr. Shotorbani was instrumental in the creation of Project Santa Fe—a recently launched initiative with like-minded executives—helping to forge new frontiers that will define future economic valuation and placement of diagnostic services. Before joining TriCore in 2014, Mr. Shotorbani served as Senior Vice President and Director of Business Development/Business Innovations at ARUP. He joined ARUP in 1984 as a medical technologist and while at ARUP advanced to positions with progressive responsibility over his 30-year tenure.

Khosrow R. Shotorbani, MBA, MT(ASCP)

President, Executive Director
Founder, CEO, Lab 2.0 Strategic Services

James M. Crawford, MD, PhD

BOARD OF DIRECTORS / CHAIR OF THE BOARD, PSFF; EXECUTIVE DIRECTOR AND SENIOR VP LABORATORY SERVICES, NORTHWELL HEALTH

Dr. James Crawford is Chair of the Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra/Northwell. And Senior Vice President of Laboratory Services for the Northwell Health System.

Jim received his bachelor’s degree from Dartmouth College (1976) and his MD and PhD degrees from Duke University (1982). After interning in Pathology at Duke University medical Center (1982 – 1983), he trained as an Anatomic Pathology resident at Brigham and Woman’s Hospital (1983 – 1987), including a fellowship in Gastrointestinal Pathology and training in 1989 at Royal free Hospital in London as a Liver Pathology Research Fellow.

From 1988 – 1996 he was a faculty member in the Department of Pathology at Brigham and Woman’s Hospital, rising to the rank of the Associate Professor and Directory of the Program in Gastrointestinal Pathology at Yale University School of Medicine. He then moved to the University of Florida College of Medicine in Gainesville, FL, where for 9 years he served as Professor and Chair of the Department of Pathology, Immunology, and Laboratory Medicine. He also served 8 years as President of the Faculty Practice Association and as Chair of the College’s Executive Fiscal Advisory Committee. Dr. Crawford is well known as a Liver Pathologist and for his research in hepatobiliary pathophysiology. He has served as Editor-in-Chief of Laboratory Investigation, Chair of the Council of Academic Societies of the Association of American Medical Colleges  (AAMC), President of the Association of Pathology Chairs (APC), and Chair of the Board of Directors of the College of American Pathologists (CAP) “PathPAC” Political Action Committee. He currently is the founding editor of the new APC journal Academic Pathology.

Through both the Association of Pathology Chairs and the College of American Pathologists, DR. Crawford has been heavily involved in advocacy for healthcare. In recent years, he has taken a leading role in advocating for the specialty of Pathology to be part of the next era of “patient-centered” healthcare, particularly with regards to Health Information Technology and the Patient-Centered Medicine Home. That includes being a founding member of Project Santa Fe, which is advancing the concept of Clinical Laboratory 20., as an evidence-based foundation for the value statements of laboratory services in the next era of American health-care.

James M. Crawford, MD, PhD

BOARD OF DIRECTORS / CHAIR OF THE BOARD, PSFF; EXECUTIVE DIRECTOR AND SENIOR VP LABORATORY SERVICES, NORTHWELL HEALTH

Dr. James Crawford is Chair of the Department of Pathology and Laboratory Medicine, Zucker School of Medicine at Hofstra/Northwell. And Senior Vice President of Laboratory Services for the Northwell Health System.

Jim received his bachelor’s degree from Dartmouth College (1976) and his MD and PhD degrees from Duke University (1982). After interning in Pathology at Duke University medical Center (1982 – 1983), he trained as an Anatomic Pathology resident at Brigham and Woman’s Hospital (1983 – 1987), including a fellowship in Gastrointestinal Pathology and training in 1989 at Royal free Hospital in London as a Liver Pathology Research Fellow.

From 1988 – 1996 he was a faculty member in the Department of Pathology at Brigham and Woman’s Hospital, rising to the rank of the Associate Professor and Directory of the Program in Gastrointestinal Pathology at Yale University School of Medicine. He then moved to the University of Florida College of Medicine in Gainesville, FL, where for 9 years he served as Professor and Chair of the Department of Pathology, Immunology, and Laboratory Medicine. He also served 8 years as President of the Faculty Practice Association and as Chair of the College’s Executive Fiscal Advisory Committee. Dr. Crawford is well known as a Liver Pathologist and for his research in hepatobiliary pathophysiology. He has served as Editor-in-Chief of Laboratory Investigation, Chair of the Council of Academic Societies of the Association of American Medical Colleges  (AAMC), President of the Association of Pathology Chairs (APC), and Chair of the Board of Directors of the College of American Pathologists (CAP) “PathPAC” Political Action Committee. He currently is the founding editor of the new APC journal Academic Pathology.

Through both the Association of Pathology Chairs and the College of American Pathologists, DR. Crawford has been heavily involved in advocacy for healthcare. In recent years, he has taken a leading role in advocating for the specialty of Pathology to be part of the next era of “patient-centered” healthcare, particularly with regards to Health Information Technology and the Patient-Centered Medicine Home. That includes being a founding member of Project Santa Fe, which is advancing the concept of Clinical Laboratory 20., as an evidence-based foundation for the value statements of laboratory services in the next era of American health-care.

James M. Crawford, MD, PhD

Chair Of The Board
Executive Director and Senior VP Laboratory Services, Northwell Health

Myra L. Wilkerson, MD

BOARD OF DIRECTORS / CHAIR, DIVISION OF LABORATORY MEDICINE, GEISINGER HEALTH SYSTEM

Myra Wilkerson is Chair, Laboratory Medicine Service Line for Geisinger. Dr. Wilkerson is responsible for oversight of all clinical and anatomic pathology laboratory services within the health system.

She joined the Geisinger team in 1999 and has helped several medical directorships over Geisinger hospital laboratories as week as the vice chair for the service line. Her subspecialty areas are cytopathology, genitourinary pathology, and laboratory informatics. Her current research interests include tissue microarrays and immunochemistry of the testicular and bladder tumors. Dr. Wilkerson recently edited and contributed four chapters to a book published by the Geisinger anatomic pathology group, the Handbook of Practical Immunohistochemistry: Frequently Asked Questions. She s one of the web authors for the companion wed site to this book, www.ihcfaq.com.

Dr Wilkerson is a part president of the Association of the Clinical Scientists and a past president of the Association for Pathology Informatics. She also currently serves on the Informatics Committee and the Clinical Informatics Steering Committee for the College of American Pathologist’s. She is on the editorial boards of three peer reviewed journals, the Annals of Clinical and Laboratory Science, the Archives of Pathology and Laboratory Medicine and the Journal of Pathology Informatics. Dr. Wilkerson received her undergraduate degree in Medical Technology from Marshall University, and then worked in the clinical laboratories at Charleston Area Medical Center before retuning to Marshall University to earn a Doctor of Medicine. She completed a combined anatomic and clinical pathology residency and cytopathology specialty training in the PennState Geisinger Health System.

Myra L. Wilkerson, MD

BOARD OF DIRECTORS / CHAIR, DIVISION OF LABORATORY MEDICINE, GEISINGER HEALTH SYSTEM

Myra Wilkerson is Chair, Laboratory Medicine Service Line for Geisinger. Dr. Wilkerson is responsible for oversight of all clinical and anatomic pathology laboratory services within the health system.

She joined the Geisinger team in 1999 and has helped several medical directorships over Geisinger hospital laboratories as week as the vice chair for the service line. Her subspecialty areas are cytopathology, genitourinary pathology, and laboratory informatics. Her current research interests include tissue microarrays and immunochemistry of the testicular and bladder tumors. Dr. Wilkerson recently edited and contributed four chapters to a book published by the Geisinger anatomic pathology group, the Handbook of Practical Immunohistochemistry: Frequently Asked Questions. She s one of the web authors for the companion wed site to this book, www.ihcfaq.com.

Dr Wilkerson is a part president of the Association of the Clinical Scientists and a past president of the Association for Pathology Informatics. She also currently serves on the Informatics Committee and the Clinical Informatics Steering Committee for the College of American Pathologist’s. She is on the editorial boards of three peer reviewed journals, the Annals of Clinical and Laboratory Science, the Archives of Pathology and Laboratory Medicine and the Journal of Pathology Informatics. Dr. Wilkerson received her undergraduate degree in Medical Technology from Marshall University, and then worked in the clinical laboratories at Charleston Area Medical Center before retuning to Marshall University to earn a Doctor of Medicine. She completed a combined anatomic and clinical pathology residency and cytopathology specialty training in the PennState Geisinger Health System.

Myra L. Wilkerson, MD

Board Treasurer
Division of Laboratory Medicine, Geisinger Health System

Mark K. Fung, MD, PhD

PROFESSOR AND VICE CHAIR POPULATION HEALTH, DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE, THE ROBERT LARNER MD COLLEGE OF MEDICINE, UNIVERSITY OF VERMONT

Dr. Mark Fung is Professor and Vice Chair of Population Health in the Department of Pathology and Laboratory Medicine at the University of Vermont (UVM). He was previously the Director of Clinical Laboratories and Vice Chair of Quality and Clinical Affairs for the Department at UVM. Prior to that, he was President of the medical staff at UVM Medical Center and Director of the Blood Bank. In addition to directing the HLA and stem cell processing laboratories, he currently serves on the board of directors for the UVM health network’s medical practice group, and co-chairs the lab sub-committee for Vermont’s ACO, OneCare Vermont.

Outside of UVM, Dr. Fung has been active nationally and internationally in promoting the use of evidence-based transfusion guidelines and the centralized reporting of transfusion service-related adverse events and errors to patient safety organizations. He completed his training in biology at Wesleyan University and medical scientist training in pathology at the University of Alabama at Birmingham. He completed his residency in pathology at Barnes Jewish Hospital and the University of Pittsburgh Medical Center, with a fellowship in transfusion medicine at the Institute for Transfusion Medicine in Pittsburgh. Dr. Fung has been at UVM since 2004.

Mark K. Fung, MD, PhD

PROFESSOR AND VICE CHAIR POPULATION HEALTH, DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE, THE ROBERT LARNER MD COLLEGE OF MEDICINE, UNIVERSITY OF VERMONT

Dr. Mark Fung is Professor and Vice Chair of Population Health in the Department of Pathology and Laboratory Medicine at the University of Vermont (UVM). He was previously the Director of Clinical Laboratories and Vice Chair of Quality and Clinical Affairs for the Department at UVM. Prior to that, he was President of the medical staff at UVM Medical Center and Director of the Blood Bank. In addition to directing the HLA and stem cell processing laboratories, he currently serves on the board of directors for the UVM health network’s medical practice group, and co-chairs the lab sub-committee for Vermont’s ACO, OneCare Vermont.

Outside of UVM, Dr. Fung has been active nationally and internationally in promoting the use of evidence-based transfusion guidelines and the centralized reporting of transfusion service-related adverse events and errors to patient safety organizations. He completed his training in biology at Wesleyan University and medical scientist training in pathology at the University of Alabama at Birmingham. He completed his residency in pathology at Barnes Jewish Hospital and the University of Pittsburgh Medical Center, with a fellowship in transfusion medicine at the Institute for Transfusion Medicine in Pittsburgh. Dr. Fung has been at UVM since 2004.

Mark K. Fung, MD, PhD

Professor and Vice Chair Population Health, Department of Pathology and Laboratory Medicine, The Robert Larner MD College of Medicine, University of Vermont

Curtis A. Hanson, MD

PROFESSOR AND VICE CHAIR, EXTRAMURAL LABORATORY AFFAIRS, DEPT. OF LABORATORY MEDICINE AND PATHOLOGY, MAYO CLINIC; CHIEF MEDICAL OFFICER, MAYO CLINIC LABORATORIES

Dr. Curt Hanson is a consultant in hematopathology at Mayo Clinic in Rochester, MN, with an academic rank of Professor of Laboratory Medicine and Pathology. He is the previous Chair of the Department of Laboratory Medicine and Pathology and is currently the Chief Medical Officer of Mayo Clinic Laboratories. He’s also Chair of the Board of Directors for the American Clinical Laboratory Association.

Dr. Hanson is a hematopathologist with expertise in bone marrow pathology, with emphasis on translational research related to the study of hematologic diseases. More recently, he has focused his clinical and academic interest on laboratory test utilization and how clinical laboratories need to adapt to a value-based reimbursement environment.

Dr. Hanson earned his medical degree from the University of Iowa. He completed his residency in anatomic/clinical pathology and a fellowship in hematopathology at the University of Minnesota.

Curtis A. Hanson, MD

PROFESSOR AND VICE CHAIR, EXTRAMURAL LABORATORY AFFAIRS, DEPT. OF LABORATORY MEDICINE AND PATHOLOGY, MAYO CLINIC; CHIEF MEDICAL OFFICER, MAYO CLINIC LABORATORIES

Dr. Curt Hanson is a consultant in hematopathology at Mayo Clinic in Rochester, MN, with an academic rank of Professor of Laboratory Medicine and Pathology. He is the previous Chair of the Department of Laboratory Medicine and Pathology and is currently the Chief Medical Officer of Mayo Clinic Laboratories. He’s also Chair of the Board of Directors for the American Clinical Laboratory Association.

Dr. Hanson is a hematopathologist with expertise in bone marrow pathology, with emphasis on translational research related to the study of hematologic diseases. More recently, he has focused his clinical and academic interest on laboratory test utilization and how clinical laboratories need to adapt to a value-based reimbursement environment.

Dr. Hanson earned his medical degree from the University of Iowa. He completed his residency in anatomic/clinical pathology and a fellowship in hematopathology at the University of Minnesota.

Curtis A. Hanson, MD

Professor and Vice Chair, Extramural Laboratory Affairs, Dept. of Laboratory Medicine and Pathology, Mayo Clinic; Chief Medical Officer, Mayo Clinic Laboratories

Karen L. Kaul, MD, PhD

BOARD OF DIRECTORS / DUCKWORTH FAMILY CHAIR OF MOLECULAR PATHOLOGY, CHAIR PATHOLOGY AND LABORATORY MEDICINE, NORTHSHORE UNIVERSITY HEALTHSYSTEM; CLINICAL PROFESSOR OF PATHOLOGY, UNIVERSITY OF CHICAGO PRITZKER SCHOOL OF MEDICINE

Dr. Karen L. Kaul is Chair of the Department of Pathology and Laboratory Medicine at NorthShore and is a Clinical Professor of Pathology at the University of Chicago’s Pritzker School of Medicine. She previously served as Director of the Molecular Diagnostics Division at NorthShore University HealthSystem. Board-certified in anatomic pathology, and molecular genetic pathology, she has been deeply involved in the development of laboratory tests for cancer, heritable, and microbial diseases.

Dr. Kaul is a past President of the Association for Molecular Pathology and served as Editor-in-Chief of the Journal of Molecular Diagnostics. She has led efforts to expand molecular pathology and personalized medicine programs at NorthShore, serving as Interim Co-Director of the Personalized Medicine Program, and expanding the tissue and genomic biorepository. She has over 100 peer-reviewed publications and recently co-edited the book Genomics in Cancer.

Dr. Kaul is the recipient of the 2008 Association for Molecular Pathology Leadership Award. She is Past President of the American Board of Pathology and serves on the ACGME Residency Review Committee for Pathology. She was an Executive Leadership in Academic Medicine fellow in 2011-2012 and served as a member of the Tapestry/SPOT Dx working group. In late 2016, she provided testimony to the bipartisan Senate Health Education Labor and Pension Committee on the contributions of lab-developed tests and procedures to personalized medicine. She’s a Board member for Laboratory 2.0 and is involved in efforts to transform the laboratory through better integration and utilization.

Karen L. Kaul, MD, PhD

BOARD OF DIRECTORS / DUCKWORTH FAMILY CHAIR OF MOLECULAR PATHOLOGY, CHAIR PATHOLOGY AND LABORATORY MEDICINE, NORTHSHORE UNIVERSITY HEALTHSYSTEM; CLINICAL PROFESSOR OF PATHOLOGY, UNIVERSITY OF CHICAGO PRITZKER SCHOOL OF MEDICINE

Dr. Karen L. Kaul is Chair of the Department of Pathology and Laboratory Medicine at NorthShore and is a Clinical Professor of Pathology at the University of Chicago’s Pritzker School of Medicine. She previously served as Director of the Molecular Diagnostics Division at NorthShore University HealthSystem. Board-certified in anatomic pathology, and molecular genetic pathology, she has been deeply involved in the development of laboratory tests for cancer, heritable, and microbial diseases.

Dr. Kaul is a past President of the Association for Molecular Pathology and served as Editor-in-Chief of the Journal of Molecular Diagnostics. She has led efforts to expand molecular pathology and personalized medicine programs at NorthShore, serving as Interim Co-Director of the Personalized Medicine Program, and expanding the tissue and genomic biorepository. She has over 100 peer-reviewed publications and recently co-edited the book Genomics in Cancer.

Dr. Kaul is the recipient of the 2008 Association for Molecular Pathology Leadership Award. She is Past President of the American Board of Pathology and serves on the ACGME Residency Review Committee for Pathology. She was an Executive Leadership in Academic Medicine fellow in 2011-2012 and served as a member of the Tapestry/SPOT Dx working group. In late 2016, she provided testimony to the bipartisan Senate Health Education Labor and Pension Committee on the contributions of lab-developed tests and procedures to personalized medicine. She’s a Board member for Laboratory 2.0 and is involved in efforts to transform the laboratory through better integration and utilization.

Karen L. Kaul, MD, PhD

Duckworth Family Chair of Molecular Pathology, Chair Pathology and Laboratory Medicine, Northshore University Healthsystem; Clinical Professor of Pathology, University of Chicago Pritzker School of Medicine

Richard J. Zarbo, MD, DMD

BOARD OF DIRECTORS / SENIOR VP AND CHAIR, PATHOLOGY AND LABORATORY MEDICINE, HENRY FORD HEALTH SYSTEM

Richard Zarbo, MD, DMD is the system chairman and KD Ward Chair of Pathology and Laboratory Medicine in the Henry Ford Health System and past-president of the United States and Canadian Academy of Pathology. He is a board-certified anatomic and clinical pathologist and an expert in head and neck pathology, laboratory quality and continuous process improvement. Dr. Zarbo is an early pioneer in laboratory quality. His initial foray in quality goes back to the 1990’s when he was instrumental in defining national benchmarks of laboratory quality through the CAP Q-Probes and Q-tracks programs. Since the early 2000’s he has endeavored to create a culture of continuous improvements throughout the Henry Ford laboratories that he integrated into System-wide Product Line.

The Henry Ford continuous improvement culture is based on s synthesis if Henry Ford’s automotive manufacturing focus on waste reduction and efficiency, the management approach of W. Edwards Deming and the Lean principles and human development of the Toyota Production System. The successful Henry Ford Production System, now in the 12th year in the Henry Ford Laboratories, is featured in Dr. Jeffrey liker’s booked – The Toyota way to Continuous Improvement: Linking Strategy and Operational Excellence to Achieve Superior Performance (2011) and The Toyota Way to Service Excellence Lean Transformation in Service Organizations (2016). The Henry Ford laboratories obtained ISO 15189 accreditation in 2013 as the largest ISO 1589 accredited integrated, multi-setting medical laboratory system in the US. Dr. Zarbo’s curriculum vitae includes over 200 peer-reviewed publications with over 50 directly related to laboratory quality. He is a clinical professor of Pathology at Wayne State University School of Medicine.

Richard J. Zarbo, MD, DMD

BOARD OF DIRECTORS / SENIOR VP AND CHAIR, PATHOLOGY AND LABORATORY MEDICINE, HENRY FORD HEALTH SYSTEM

Richard Zarbo, MD, DMD is the system chairman and KD Ward Chair of Pathology and Laboratory Medicine in the Henry Ford Health System and past-president of the United States and Canadian Academy of Pathology. He is a board-certified anatomic and clinical pathologist and an expert in head and neck pathology, laboratory quality and continuous process improvement. Dr. Zarbo is an early pioneer in laboratory quality. His initial foray in quality goes back to the 1990’s when he was instrumental in defining national benchmarks of laboratory quality through the CAP Q-Probes and Q-tracks programs. Since the early 2000’s he has endeavored to create a culture of continuous improvements throughout the Henry Ford laboratories that he integrated into System-wide Product Line.

The Henry Ford continuous improvement culture is based on s synthesis if Henry Ford’s automotive manufacturing focus on waste reduction and efficiency, the management approach of W. Edwards Deming and the Lean principles and human development of the Toyota Production System. The successful Henry Ford Production System, now in the 12th year in the Henry Ford Laboratories, is featured in Dr. Jeffrey liker’s booked – The Toyota way to Continuous Improvement: Linking Strategy and Operational Excellence to Achieve Superior Performance (2011) and The Toyota Way to Service Excellence Lean Transformation in Service Organizations (2016). The Henry Ford laboratories obtained ISO 15189 accreditation in 2013 as the largest ISO 1589 accredited integrated, multi-setting medical laboratory system in the US. Dr. Zarbo’s curriculum vitae includes over 200 peer-reviewed publications with over 50 directly related to laboratory quality. He is a clinical professor of Pathology at Wayne State University School of Medicine.

Richard J. Zarbo, MD, DMD

Senior VP and Chair, Pathology and Laboratory Medicine, Henry Ford Health System

2023 CL2.0 Workshop Agenda

Join the crucial conversation with fellow leaders across the industry as we define the future business model for the clinical laboratory.  Represented at this workshop is a tremendously respected collective body of knowledge, take your seat at the table and make an important contribution as critical questions are addressed that will shape the future of our collective industry.

March 5, 2023 – Welcome Reception

5:30pm – 7:30pm

March 6, 2023 – CL2.0 Workshop Day One

8 – 8:20am: Welcome to Convergence!  

8:20 – 8:40am: How Covid Crashed the System
A Guide to Fixing American Health Care

  • David B. Nash, MD, MBA
    Founding Dean Emeritus
    Jefferson College of Population Health

8:40 – 9am: Both/And
Medicine & Public Health Together

  • Katie Kaney, DrPH, MBA, FACHE
    Author: Both/ And: Medicine & Public Health Together
    Founder: Whole Person Index

9 – 10am: The Power of Purchasing as We Transition to Value  
We all talk about value, yet we get paid for volume.  How do we align our incentives to drive change? What does value-based payment look like? How do we change the paradigm to improve outcome and reduce ‘total cost,’ not just reduce ‘cost per’ unit?   Premier Inc leads a deep-dive discussion about the future of value-based contracting for the laboratory industry as we anticipate a value-based business model, purchasing model and payment model.

  • Peter Aftosmes, VP of Strategic Supplier Engagement
    Premier Inc
  • Mark D. Povroznik, PharmD, Chief Quality Officer, WVU Medicine, United Hospital Center

10:00am – 10:30am:  BREAK and book signing!

10:30am – 12:30am: CL2.0 Customer Panel:  The Healthcare Industry is Navigating the Strategic Inflection Point
How is the healthcare industry reimagining the future to deliver the right care, for the right population, at the right time, and at the right cost?  Leaders representing CMS, CDC, Public Health, Population Health and Major Health Systems C-Suite weigh in on their visions and plans for navigating healthcare’s transition from volume to value.

  • Facilitator: Mark D. Dixon, Rph, MHA, FACHE
  • Dr. Lee Fleisher, MD
    Chief Medical Officer
    Centers for Medicare and Medicaid Services (CMS)
  • Nancy E. Cornish MD
    Medical Officer, Senior Advisor for Quality and Safety
    Center for Surveillance, Epidemiology and Laboratory Services
    Centers for Disease Control and Prevention (CDC)
  • Julia Connell
    Director, Member Insights
    Health Management Academy
  • Katie Kaney, DrPH, MBA, FACHE
    Author: Both/ And: Medicine & Public Health Together
    Founder: Whole Person Index
  • David B. Nash, MD, MBA
    Founding Dean Emeritus
    Jefferson College of Population Health

12:30 – 1:30pm: LUNCH

1:30 – 3pm: Improving Clinical & Financial Outcomes Using the CL2.0 Model
If future is about early detection, intervention, prevention, cost avoidance and risk management, what are the opportunities for the clinical lab to proactively risk stratify a  population to help triage care at early stages? What could chronic condition surveillance look like?  Project Santa Fe Foundation faculty share thought leadership through CL2.0 Position Statements, as well as multi-institutional work on CL2.0 Lab-Initiated Care Models.

  • Mark Dixon, Rph, MHA, FACHE
  •  James M. Crawford, MD, PhD,
    Sr VP of Laboratory Services, Northwell Health
  • Mark K. Fung, MD, PhD,
    Vice-Chair Population Health, Dept of Pathology & Laboratory Medicine, University of Vermont Medical
  • Elizabeth Montgomery,
    VP Learning Strategies, National Kidney Foundation
  • Kathy Swanson,
    Faculty, Project Santa Fe Foundation

3:00 – 3:15PM: BREAK

3:15 – 4:45pm: CL2.0 Business Model Panel for Lab-initiated Value-based Care
Technology doesn’t disrupt, payment does!  What is the right payment leading to the right care for the right population at the right time?  What is the business model for lab-initiated care?  How will we monetize lab’s quantifiable value amplifying the key objectives of population health?  This session discusses the alternative business model elements, alternative payment tools, tips, and frameworks that can help laboratories looking to create and execute a strategy for the future.

  • Gaurav Sharma, MD,
    Medical Director Department of Pathology, Laboratory Medicine, Henry Ford Medical Center
  • Chris Garcia, MD
    Medical Director, Computational Pathology and AI,
    Mayo Clinic
  • Michael Crossey, MD, PhD
    Project Santa Fe Foundation Board Member
    Medical Director, TriCore
  • Lena Chaihorsky
    Vice President
    Payor Innovation, Alva10 Inc.

4:45 – 7pm: Day One Summary and Networking Reception

March 7, 2023 – CL2.0 Workshop Day Two

8 – 8:10am: Welcome back

8:10 – 10am: Comprehensive Data Platform to Catalyze Clinical Action
The CL2.0 value proposition is based on near real-time, longitudinal lab data coupled with social determinants of health to create a comprehensive data platform that catalyzes clinical action. This session explores the evolving care models, patient access channels and consumer engagement channels that create the data longitudinal platform of the future.

  • David Johnson,
    CEO
    4sight Health
  • Karissa Culbreath, PhD
    Medical Director and Division Chief, Infectious Disease
    TriCore
  • Dwayne Breining, MD
    Executive Director
    Northwell Health Laboratories
  • Kapil Parakh, MD, MPH, PhD
    Medical Lead
    Google/Fitbit

10 – 10:30am: BREAK

10:30 – 12pm: Industry’s Role in Amplifying the Comprehensive Data Platform
Industry serves a unique role in harnessing, curating, and amplifying the comprehensive data platform to drive clinical strategies of early detection and early care management.  CL2.0  Industry Partners discuss the power of this role, as well as how Industry can help influence necessary policy re-alignment  to properly incentivize value-based care?

  • Facilitator: Khosrow Shotorbani
    President & Executive Director, PSFF
  • Tobin Efferen, MD, MS,
    Senior Medical Director, Medical Scientific Affairs, Beckman Coulter
  • Andy Hay,
    President & CEO, Sysmex America, Inc.
  • Hong Hong Vice President, U.S. Head of Access & Government Affairs, Roche Diagnostics
  • Veena Joy, MSc, PhD,
    Sr. Manager – US Autoimmunity, Thermo Fisher Scientific
  • Melanie Pollan, PhD, MT(ASCP),
    Sr. Director, Medical & Scientific Affairs, Siemens Healthcare Diagnostic, Inc.
  • Tricia Ravalico,
    Global Director, Scientific Leadership and Education, Core Diagnostics, Abbott
  • Maricel Roberts,
    Managing Director, Americas, Inpeco
  • Kelley Sager,
    VP & GM, Clinical Decision Support Solutions, Beckman Coulter
  • Meghan Thelen, JD,
    Sr. Director, Value-Based Healthcare, bioMérieux

12 – 1pm:  LUNCH

1 – 2:30pm: PSFF Board of Directors Panel:  Pathology Leadership Driving Change
The CL2.0 Movement is about pathology and lab leaders stepping outside of the four walls of the lab and taking a seat at the table helping to design the future care models.  Are we aligning the quantifiable attributes of the clinical lab with our organization’s strategy?  Are we measuring what matters?  The Project Santa Fe Foundation Board of Directors explores these questions that will inform the pathology and lab leader job descriptions of the future.

  • Facilitator: Bob McGonnagle,
    Founding Publisher, CAP Today
  • Khosrow Shotorbani
    President & Executive Director
    Project Santa Fe Foundation
  • James M. Crawford, MD, PhD
    Sr VP of Laboratory Services
    Northwell Health;
  • Mark K. Fung, MD, PhD
    Vice-Chair Population Health
    Dept of Pathology & Laboratory Medicine, University of Vermont Medical
  • Arand Pierce, MD, Chief Medical Officer, TriCore
  • Karen L. Kaul, MD, PhD
    Chair of Pathology & Laboratory Medicine
    Northshore University Health
  • Myra Wilkerson, MD
    Chair, Division of Laboratory Medicine,
    Geisinger Health System

2:30 – 3pm: Future of the CL2.0 Movement - A “Careholder” Discussion
Project Santa Fe Foundation is embarking upon its 7th year. Engage in an interactive discussion about the role of the movement in leading change for our collective industry.